Welcome to our dedicated page for Poseida Therapeutics news (Ticker: PSTX), a resource for investors and traders seeking the latest updates and insights on Poseida Therapeutics stock.
Poseida Therapeutics, Inc. (Nasdaq: PSTX) is a clinical-stage biopharmaceutical company that specializes in developing innovative cell and gene therapies aimed at curing certain cancers and rare diseases. The company's core focus is on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with unmet medical needs. Poseida's pipeline includes autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates, initially targeting hematological malignancies and solid tumors.
Poseida boasts best-in-class genome engineering capabilities, utilizing proprietary tools like the piggyBac™ DNA modification system, nextGEN™ CRISPR, XTN™ TALEN, and the footprint-free™ gene editing system. These tools are virus-free and offer surgical precision in gene editing, enabling the development of highly effective therapies.
Recent achievements include significant advancements in the company's lead program, P-BCMA-ALLO1, a novel BCMA-targeted allogeneic CAR-T therapy for treating relapsed/refractory multiple myeloma (RRMM). The FDA recently granted Orphan Drug Designation for P-BCMA-ALLO1, underscoring its potential to meet high unmet medical needs. Poseida is investigating this therapy in collaboration with Roche, with promising preliminary data presented at major scientific conferences.
In addition to its focus on cancer, Poseida is also advancing genetic medicines for rare diseases. The company has highlighted progress in its gene therapy pipeline, especially for conditions like Hereditary Angioedema and Hemophilia A. These programs employ fully non-viral approaches, leveraging Poseida's advanced genetic engineering and delivery platforms.
Poseida has formed strategic collaborations with industry giants like Janssen and Roche, enhancing its capacity to bring innovative therapies to market. The company also recently entered into a research collaboration with Xyphos Biosciences, a subsidiary of Astellas, to develop novel convertibleCAR® programs targeting solid tumors.
Financially, Poseida reported revenues of $28.1 million for Q1 2024, a substantial increase from the previous year, primarily driven by collaborations with Astellas and Roche. With a strong cash position and additional funding from strategic partnerships, Poseida is well-positioned to advance its pipeline and achieve key milestones in 2024 and beyond.
Learn more about Poseida Therapeutics and its groundbreaking work by visiting www.poseida.com and connecting with the company on X and LinkedIn.
Poseida Therapeutics (Nasdaq: PSTX) announced interim results from its Phase 1 trial of P-PSMA-101, an autologous CAR-T product for metastatic castrate-resistant prostate cancer (mCRPC), presented at the ASCO GU Symposium. Out of 14 evaluable patients, 71% showed PSA declines, with one achieving complete tumor elimination. The trial demonstrated a favorable safety profile, with manageable adverse events, including cytokine release syndrome. The ongoing study aims to further assess safety and efficacy, utilizing Poseida's proprietary genetic engineering technologies.
Poseida Therapeutics (Nasdaq: PSTX) will hold its second annual Virtual R&D Day on February 23, 2022, from 10:00 am to 1:30 pm ET. The event will feature presentations from executives, researchers, and key opinion leaders, focusing on the company's genetic engineering technologies and cell and gene therapy programs. Notable speakers include Dr. Susan F. Slovin from Memorial Sloan Kettering and Dr. Luca Gattinoni from the University of Regensburg. Registration is available on Poseida's website, with a replay of the webcast accessible for 30 days after the event.
Poseida Therapeutics, Inc. (Nasdaq: PSTX) announced the appointment of Eric Ostertag as Executive Chairman and Mark Gergen as CEO effective February 1, 2022. Both will continue on the Board of Directors. The company is focusing on advancing its gene and cell therapy programs, including partnerships with Takeda, valued at up to $3.6 billion. Poseida also outlined its 2022 objectives, highlighting ongoing clinical trials for its P-PSMA-101 and P-BCMA-ALLO1 product candidates. The company’s R&D Day is set for February 23, 2022, to showcase progress and future strategies.
Poseida Therapeutics (Nasdaq: PSTX) announced FDA clearance for its Investigational New Drug (IND) application for P-MUC1C-ALLO1, an allogeneic CAR-T product targeting solid tumors. This marks Poseida's second IND clearance in 2021, following P-BCMA-ALLO1. The upcoming Phase 1 trial will evaluate P-MUC1C-ALLO1's safety and efficacy in patients with advanced epithelial-derived solid tumors. The product is designed to reduce alloreactivity, potentially allowing treatment from a single manufacturing run. Initial clinical data is expected in 2022.
Poseida Therapeutics (PSTX) announced interim results from its Phase 1/2 PRIME clinical trial for P-BCMA-101, a CAR-T therapy for relapsed/refractory multiple myeloma, at the 2021 ASH Annual Meeting. The therapy was well tolerated, showing a 78% overall response rate and significant anti-tumor activity. The company is transitioning to its allogeneic program, P-BCMA-ALLO1, which leverages insights from the trial. The IND for P-BCMA-ALLO1 was approved by the FDA in August 2021, with expectations to present more data in 2022.
Poseida Therapeutics (Nasdaq: PSTX) reported its third-quarter 2021 program updates and financial results, demonstrating progress in clinical trials and partnerships. FDA cleared the IND for P-BCMA-ALLO1, their first allogeneic CAR-T therapy, focusing on multiple myeloma. The company revealed a collaboration with Takeda, earning $45 million to develop gene therapies. Research and development expenses rose to $32.5 million, leading to a net loss of $42.4 million for the quarter. As of September 30, 2021, Poseida held $197.8 million in cash and equivalents.
Poseida Therapeutics (PSTX) announced the presentation of preclinical data for its allogeneic CAR-T candidates, P-BCMA-ALLO1 and P-MUC1C-ALLO1, at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting from November 10-14. The data highlights potent antitumor activity and the benefits of their proprietary genetic engineering technologies. P-BCMA-ALLO1 has received FDA IND clearance and is entering Phase 1 trials. The company aims to leverage its manufacturing process to produce numerous patient doses, potentially reducing costs significantly.
Poseida Therapeutics (Nasdaq: PSTX) announced participation in two upcoming virtual investor conferences. The Stifel 2021 Virtual Healthcare Conference is scheduled for November 16, 2021, at 2:40 PM ET, while the Piper Sandler 33rd Annual Virtual Healthcare Conference will take place on November 22, 2021, with a pre-record available at 10:00 AM ET. Webcasts will be accessible on the Poseida website for 30 days post-event. Poseida utilizes proprietary genetic engineering to develop advanced cell and gene therapeutics.
Poseida Therapeutics (Nasdaq: PSTX) has announced new executive leadership appointments effective immediately. Johanna Mylet is the new Chief Financial Officer, Devon Shedlock becomes Chief Scientific Officer for Cell Therapies, Kristin Martin takes on the role of Chief People and Administration Officer, and Lisa Portale is now Senior Vice President for Regulatory Affairs. The company aims to enhance its capabilities in cell and gene therapy following a strategic collaboration with Takeda. These changes support Poseida's mission to develop transformative therapies for cancer and rare diseases.
Poseida Therapeutics (Nasdaq: PSTX) announced a collaboration and exclusive license agreement with Takeda Pharmaceutical Company to develop up to eight gene therapies using Poseida's innovative genetic engineering technologies. The initial focus will be on non-viral in vivo gene therapy programs, including a Hemophilia A program. Poseida will receive an upfront payment of $45 million, with potential additional payments exceeding $2.7 billion, depending on milestone achievements. The partnership aims to provide novel therapies for rare genetic diseases and enhance Poseida's development capabilities.
FAQ
What is the current stock price of Poseida Therapeutics (PSTX)?
What is the market cap of Poseida Therapeutics (PSTX)?
What is Poseida Therapeutics, Inc.?
What are Poseida's core technologies?
What is P-BCMA-ALLO1?
Who are Poseida's strategic partners?
What diseases is Poseida targeting with its gene therapies?
What recent financial achievements has Poseida reported?
What is Poseida's approach to gene editing?
How can I learn more about Poseida Therapeutics?
What is the significance of the Orphan Drug Designation for P-BCMA-ALLO1?
What are Poseida's future plans?
